PEAK BIO Trademark

Trademark Overview

On Tuesday, January 25, 2022, a trademark application was filed for PEAK BIO with the United States Patent and Trademark Office. The USPTO has given the PEAK BIO trademark a serial number of 97238206. The federal status of this trademark filing is SU - REGISTRATION REVIEW COMPLETE as of Friday, March 22, 2024. This trademark is owned by pH Pharma Inc.. The PEAK BIO trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Drug development research in the field of biotechnology; pharmaceutical drug development services
peak bio

General Information

Serial Number97238206
Word MarkPEAK BIO
Filing DateTuesday, January 25, 2022
Status819 - SU - REGISTRATION REVIEW COMPLETE
Status DateFriday, March 22, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 20, 2023

Trademark Statements

Disclaimer with Predetermined Text"BIO"
Goods and ServicesDrug development research in the field of biotechnology; pharmaceutical drug development services

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, January 31, 2022
Primary Code042
First Use Anywhere DateTuesday, March 1, 2022
First Use In Commerce DateTuesday, March 1, 2022

Trademark Owner History

Party NamePEAK BIO, INC.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPALO ALTO, CA 94303
Party NamePEAK BIO, INC.
Party Type12 - New Owner Before Publication
Legal Entity Type03 - Corporation
AddressPALO ALTO, CA 94303
Party NamePEAK BIO CA, INC.
Party Type11 - New Owner Before Publication
Legal Entity Type03 - Corporation
AddressPALO ALTO, CA 94303
Party NamepH Pharma Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressPalo Alto, CA 94303

Trademark Events

Event DateEvent Description
Saturday, March 23, 2024NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Friday, March 22, 2024ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Wednesday, February 28, 2024STATEMENT OF USE PROCESSING COMPLETE
Friday, February 2, 2024USE AMENDMENT FILED
Saturday, February 24, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, February 2, 2024TEAS STATEMENT OF USE RECEIVED
Tuesday, August 15, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, June 20, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 20, 2023PUBLISHED FOR OPPOSITION
Wednesday, May 31, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 16, 2023LAW OFFICE PUBLICATION REVIEW COMPLETED
Tuesday, May 9, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 3, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, May 3, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, May 3, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, May 3, 2023ASSIGNED TO LIE
Wednesday, February 1, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, February 1, 2023AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Wednesday, January 25, 2023AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Wednesday, January 11, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, January 11, 2023TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Wednesday, January 11, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, January 11, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, November 9, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, November 9, 2022NON-FINAL ACTION E-MAILED
Wednesday, November 9, 2022NON-FINAL ACTION WRITTEN
Thursday, November 3, 2022ASSIGNED TO EXAMINER
Monday, January 31, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, January 28, 2022NEW APPLICATION ENTERED

Related Keywords

peak drug development pharmaceutical services field research biotechnology